Pinostrobin chalcone for COVID-19
c19early.org
COVID-19 Treatment Clinical Evidence
COVID-19 involves the interplay of 400+ viral and host proteins and factors, providing many therapeutic targets.
c19early analyzes 6,000+ studies for 210+ treatments—over 17 million hours of research.
Only three high-profit early treatments are approved in the US.
In reality, many treatments reduce risk,
with 25 low-cost treatments approved across 163 countries.
-
Naso/
oropharyngeal treatment Effective Treatment directly to the primary source of initial infection. -
Healthy lifestyles Protective Exercise, sunlight, a healthy diet, and good sleep all reduce risk.
-
Immune support Effective Vitamins A, C, D, and zinc show reduced risk, as with other viruses.
-
Thermotherapy Effective Methods for increasing internal body temperature, enhancing immune system function.
-
Systemic agents Effective Many systemic agents reduce risk, and may be required when infection progresses.
-
High-profit systemic agents Conditional Effective, but with greater access and cost barriers.
-
Monoclonal antibodies Limited Utility Effective but rarely used—high cost, variant dependence, IV/SC admin.
-
Acetaminophen Harmful Increased risk of severe outcomes and mortality.
-
Remdesivir Harmful Increased mortality with longer followup. Increased kidney and liver injury, cardiac disorders.
Pinostrobin chalcone may be beneficial for
COVID-19 according to the study below.
COVID-19 involves the interplay of 400+ viral and host proteins and factors providing many therapeutic targets.
Scientists have proposed 11,000+ potential treatments.
c19early.org analyzes
210+ treatments.
We have not reviewed pinostrobin chalcone in detail.
, Protein Interaction Analysis and Molecular Simulation of the Anti‐Inflammatory Activities in Melaleuca cajuputi Extract Against COVID‐19, International Journal of Inflammation, doi:10.1155/ijin/5568294
Coronavirus disease‐19 (COVID‐19) is correlated to a severe condition caused by a cytokine storm during which numerous proinflammatory cytokines, including interleukin‐6 (IL‐6) are released. IL‐6 is a critical driver in the COVID‐19 inflammatory state, and the inhibition is considered a potential treatment approach to prevent serious complications. Meanwhile, Melaleuca cajuputi is a plant with antibacterial, antiviral, anti‐inflammatory, and antioxidant activities. Therefore, this aimed to investigate the anti‐inflammatory potential of M. cajuputi in silico. Extraction of leaves was conducted by using 96% ethanol, followed by fractionation to obtain active compounds. Subsequently, LC/MS and GC/MS analyses were performed to obtain active compound profiling. Protein‐protein interaction (PPI), as well as molecular docking and dynamic analyses, were performed to examine interaction of active compounds of M. cajuputi with IL‐6. The results showed that 30 protein nodes played a significant role in COVID‐19 cytokine storm and eight active compounds had interactions with IL‐6. Among the active compounds, pinostrobin chalcone had the best delta G interaction with IL‐6. In conclusion, M. cajuputi has potential activity as an anti‐inflammatory agent against COVID‐19.